SOLTF Quote, Financials, Valuation and Earnings

Healios KK has a net margin of -11.44% compared to Nxera Pharma's net margin of -6742.11%. Nxera Pharma's return on equity of -8.65% beat Healios KK's return on equity of -196.15%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than Healios KK, analysts believe Nxera Pharma is more attractive than Healios KK.

Nxera Pharma has a beta of 0.374, which suggesting that the stock is 62.646% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $43.6M, which are larger than Healios KK quarterly revenues of $249.2K. Nxera Pharma's net income of -$5M is higher than Healios KK's net income of -$16.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.85x versus 83.05x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -11.44% compared to Nxera Pharma's net margin of -24.41%. Nxera Pharma's return on equity of -8.65% beat PeptiDream's return on equity of 34.1%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than PeptiDream, analysts believe Nxera Pharma is more attractive than PeptiDream.

Nxera Pharma has a beta of 0.374, which suggesting that the stock is 62.646% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $43.6M, which are larger than PeptiDream quarterly revenues of $27.8M. Nxera Pharma's net income of -$5M is higher than PeptiDream's net income of -$6.8M. Notably, Nxera Pharma's price-to-earnings ratio is -- while PeptiDream's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.85x versus 4.93x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

SanBio has a net margin of -11.44% compared to Nxera Pharma's net margin of --. Nxera Pharma's return on equity of -8.65% beat SanBio's return on equity of --.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma has higher upside potential than SanBio, analysts believe Nxera Pharma is more attractive than SanBio.

Nxera Pharma has a beta of 0.374, which suggesting that the stock is 62.646% less volatile than S&P 500. In comparison SanBio has a beta of -0.570, suggesting its less volatile than the S&P 500 by 156.993%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.

Nxera Pharma quarterly revenues are $43.6M, which are larger than SanBio quarterly revenues of --. Nxera Pharma's net income of -$5M is higher than SanBio's net income of -$10.3M. Notably, Nxera Pharma's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.85x versus 242.30x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -11.44% compared to Nxera Pharma's net margin of -9.79%. Nxera Pharma's return on equity of -8.65% beat Takeda Pharmaceutical's return on equity of 1.49%.

Nxera Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.00 which suggests that it could grow by 15.46%. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

Nxera Pharma has a beta of 0.374, which suggesting that the stock is 62.646% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

Nxera Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.52% to investors and pays a quarterly dividend of $0.34 per share. Nxera Pharma pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend.

Nxera Pharma quarterly revenues are $43.6M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Nxera Pharma's net income of -$5M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Nxera Pharma's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 67.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma is 2.85x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.